U.S. Study Suggests GLP-1 RA Drugs Are Associated with Small Increase in Ischemic Optic Neuropathy
A target trial emulation found that people with type 2 diabetes who start glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk for ischemic optic neuropathy (ION), a…
Read the full articleYou might also wanna read
Study Probes Absolute Risk for ION With GLP-1 Agents
In patients with type 2 diabetes, GLP-1 RAs may be associated with a higher incidence of ischemic optic neuropathy than other medications, c
GLP-1 Receptor Agonists and Eye Safety: Examining the NAION Risk at ADA 2025
Do their associations with nonarteritic anterior ischemic optic neuropathy and other adverse outcomes make these drugs more risky than benef
mdsc.pe·14h agoGLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits
(MedPage Today) -- Note that some links may require registration or subscription. A cohort study found that diabetes patients taking GLP-1 r
Updates in Non-Arteritic Ischemic Optic Neuropathy - Part 2
In the second episode of this two-part series, Drs. Justin Abbatemarco, Valérie Biousse, and Nancy J. Newman discuss the risk of non-arterit
AI Imaging Reveals Obesity-Related Nerve Damage; Questions Raised About GLP-1 Drug Effects on Peripheral Nerves
Fascinating nervous system imaging reveals previously unseen obesity-related nerve damage in mice and humans — and some of it may be linked
medscape.com·8d ago
GLP-1 Receptor Agonists Linked to Small Risk of Smell and Taste Disturbances in Type 2 Diabetes
The absolute risk appears low, but new data suggest small changes in smell and taste with GLP-1 treatment may exceed those already associate
mdsc.pe·14d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.